Keymed Biosciences Inc. has announced the publication of the latest clinical trial results for their bispecific antibody treatment, CM336, in the New England Journal of Medicine. Conducted by Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, the study reports on the efficacy of CM336 in treating patients with refractory autoimmune hemolytic anemia (AIHA) following CD19 CAR T-Cell Therapy. Two patients showed rapid disease improvement, achieving partial remission within days and maintaining sustained remission for over six months without further immunosuppressive therapies. The study highlights CM336's potential as a treatment option, demonstrating positive efficacy signals and a favorable safety profile.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.